BPC-157 has gained significant attention in sports medicine and among athletes because of its proposed ability to support tissue healing and recovery. Animal and laboratory studies have reported potentially beneficial effects involving muscle, tendon, ligament, gastrointestinal, and bone healing. However, the enthusiasm surrounding BPC-157 has moved considerably faster than the clinical evidence. For athletes considering BPC-157, understanding what is known and what remains unknown is particularly important.

What exactly is BPC-157?

One important consideration is that “body protein compound” or BPC-157 is not necessarily one standardized pharmaceutical product. It is also known as PL 14736, Bepecin, or PL-10. BPC-157 may be encountered in different chemical forms, including BPC-157 free base and BPC-157 acetate. This distinction matters because these are considered different active pharmaceutical ingredients by the FDA. The FDA evaluated the two forms separately after noting inconsistent identification of the form being nominated for potential compounding.[1]

Different chemical forms and manufacturing processes can affect a peptide’s purity, stability, aggregation, and other quality characteristics. The FDA noted that BPC-157 free base and acetate were not adequately characterized and raised concerns regarding peptide impurities, aggregates, microbial quality, endotoxins, and other critical quality attributes.[1] As of August 2026, the FDA’s Adverse Event Monitoring System has logged 9 serious cases for BPC-157 (0 deaths); 7 of 9 were product issues (e.g., quality/contamination), not adverse reactions.[1] For an athlete, this means that a product labeled simply “BPC-157” does not necessarily communicate the exact chemical form, manufacturing quality, or consistency of the product being used.

Most importantly, BPC-157 is not an FDA-approved drug. The FDA briefing found no approved product containing BPC-157-related substances in any country and concluded that available evidence was insufficient to establish their safety or effectiveness.[1] Therefore, BPC-157 should be viewed as an experimental substance, rather than an established treatment for sports injuries or recovery.

What does the evidence actually show?

The strongest evidence supporting BPC-157 comes from preclinical research. The 2025 systematic review by Vasireddi et al., Emerging Use of BPC-157 in Orthopaedic Sports Medicine, identified 36 studies, of which 35 were preclinical and only one was a clinical study.[2] Preclinical studies suggested potential improvements in muscle, tendon, ligament, and bone healing. Proposed mechanisms include effects on vascularity, vascular endothelial growth factor expression, inflammation, and tendon fibroblast activity.[2]

These findings are scientifically interesting, but animal and laboratory results cannot automatically be translated into clinical benefit in humans. The systematic review ultimately characterized the available evidence as predominantly low-level evidence and emphasized the lack of clinical safety data.[2]

One of the more interesting pieces of human evidence comes from a retrospective review of BPC-157 use in patients with chronic knee pain.[3] In the study, 12 patients were included in the outcome analysis, and 7 reported subjective improvement lasting more than 6 months following an intra-articular injection.[3]

At first glance, these results are encouraging. However, the study has important limitations. It was retrospective, lacked a placebo or control group, involved a small number of patients, and involved BPC-157 administered in combination with another peptide in some patients. Due to these limitations, the findings can demonstrate an interesting clinical observation, but they cannot establish that BPC-157 caused the improvement.

The FDA similarly identified only a small number of human studies involving BPC-157.[1] These studies involved different routes and doses including rectal, intra-articular, intravesical, and intravenous administration. Although no serious adverse events were reported in those studies, they were small, short in duration, and provided limited safety monitoring. Human pharmacokinetic information also remains inadequate.[1]

In other words, the current evidence provides a reason to continue studying BPC-157, not a reason to consider it a proven therapy.

What does this mean for competitive athletes?

There is another consideration that is particularly important for athletes which is that BPC-157 is prohibited in sport.

The World Anti-Doping Agency (WADA) added BPC-157 to the Prohibited List under S0: Non-Approved Substances in 2022. BPC-157 remains prohibited under the current 2026 WADA framework.[4] The U.S. Anti-Doping Agency (USADA) likewise identifies BPC-157 as prohibited and emphasizes that it is not approved for human clinical use and has no established safe dose or proven efficacy.[5]

The distinction that a substance does not need to be an FDA-approved drug to be prohibited in sport is very important. An athlete could therefore face anti-doping consequences from BPC-157 use even though the substance is not an FDA-approved medication.

Athletes should also remember that anti-doping status can depend on the governing organization and competition. Checking the current WADA Prohibited List and resources such as Global DRO before using medications or supplements is an important part of reducing avoidable risk.[4,6]

Are there safer approaches to recovery?

Rather than searching for a direct replacement for BPC-157, athletes may benefit from considering evidence-based strategies that support recovery through established mechanisms.

For example, adequate protein intake supports muscle protein synthesis, repair, and recovery, while creatine monohydrate has substantial human evidence supporting improvements in strength, power, and repeated high-intensity exercise.[7] These interventions do not mimic the proposed mechanism of BPC-157 and should not be considered equivalent treatments for an injury. However, they have a substantially larger human evidence base and established roles in sports nutrition.

For athletes who use supplements, product quality is another consideration. USADA recommends choosing third-party certified supplements because contamination with prohibited substances is possible; certification can reduce this risk, although it cannot eliminate it entirely.[8]

Ultimately, recovery should also focus on interventions with established clinical evidence, such as appropriate rehabilitation, nutrition, sleep, and individualized management of the underlying injury.

Key Takeaways for Sports Pharmacy Practice

BPC-157 is an intriguing peptide with promising preclinical findings but very limited human evidence. The retrospective knee-pain data provide an interesting clinical signal, but they are not sufficient to establish efficacy. The systematic review reinforces the same conclusion: most available research is preclinical, while high-quality human evidence remains lacking.

The uncertainty extends beyond effectiveness. Different forms of BPC-157, including free base and acetate, raise important questions about product identity and quality, while the FDA has identified concerns regarding characterization, impurities, aggregation, and immunogenicity.

For athletes, the decision is even more consequential because BPC-157 is prohibited under WADA’s S0 category. Until better-quality clinical evidence establishes its safety and effectiveness, and its regulatory and anti-doping status changes, BPC-157 should not be viewed as an established recovery treatment.

For a quick reference sheet on BPC-157, we refer you to our BPC-157 Just the Evidence sheet that you can find in our Sport Pharmacy Network Shop and is available for free for Sport Pharmacy Network Members. The Just the Evidence approach is not to dismiss emerging therapies simply because the evidence is incomplete. Instead, it is to put promising findings into context. BPC-157 may ultimately prove to have a role in medicine, but today, the evidence supports continued research, not routine clinical use or use by competitive athletes.

BeSafeRx

Before purchasing any medication or health product online, it is important to consult with a licensed healthcare provider and do your due diligence to ensure you are purchasing from a legitimate, safe source. Online pharmacies can vary widely in quality and legitimacy, and products obtained from unsafe sources may be counterfeit, contaminated, or contain incorrect ingredients or doses. An excellent resource for evaluating online pharmacies is the FDA’s BeSafeRx program, which provides tools and information to help consumers identify safe and legitimate online pharmacies.[9]

Written By Sophia Mankowski, BS, MBA, PharmD Candidate at West Virginia University

Sophia is a former athlete who played four years of division 1 soccer at the University of Tennessee-Martin followed by a year of division 2 soccer at the University of Charleston while beginning her student-pharmacist journey. Currently on her APPE rotation with SportPharm, she is very excited to learn more about the advancements of pharmacy within the sports medicine world!

References

1. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Briefing Document: BPC-157-Related Bulk Drug Substances. Presented at the PCAC meeting, July 23–24, 2026. https://www.fda.gov/media/193342/download

2. Vasireddi, N., Hahamyan, H., Salata, M. J., Karns, M., Calcei, J. G., Voos, J. E., & Apostolakos, J. M. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery, 21(4), 485–495. https://doi.org/10.1177/15563316251355551

3. Lee, E., & Padgett, B. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 27(4), 8–13.

4. World Anti-Doping Agency. 2026 Prohibited List. Effective January 1, 2026. https://www.wada-ama.org/en/resources/2026-prohibited-list

5. U.S. Anti-Doping Agency. BPC-157: Experimental Peptide Creates Risk for Athletes. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/

6. Global Drug Reference Online (Global DRO). https://www.globaldro.com

7. Kreider, R. B., Kalman, D. S., Antonio, J., Ziegenfuss, T. N., Wildman, R., Collins, R., Candow, D. G., Kleiner, S. M., Almada, A. L., & Lopez, H. L. (2017). International Society of Sports Nutrition position stand: Safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition, 14(1), 18. https://doi.org/10.1186/s12970-017-0173-z

8. U.S. Anti-Doping Agency. Reduce Your Risk from Supplements. https://www.usada.org/spirit-of-sport/how-to-reduce-your-risk-from-supplements/

9. U.S. Food and Drug Administration. BeSafeRx: Know Your Online Pharmacy. https://www.fda.gov/drugs/buying-using-medicine-safely/be-safely-buying-medicine-online

Become a Member 

If you want real-time clinical cases, webinars, evidence-based sports supplementation resources, continuing education, anti-doping resources, and access to exclusive digital content, join the Sports Pharmacy Network here.

Want to receive the latest updates from the Sports Pharmacy Network?

Subscribe today